Microbot Medical Inc. (MBOT) Stock Price & Analysis
Microbot Medical Inc. (MBOT) fell 2.84% to USD 1.71 as of July 25, 2026 at 10:04 UTC, according to Nexqual real-time market data.
MBOT last closed at USD 1.76; the session ranged USD 1.7–1.77 on volume of 364,418 shares. Market capitalization is $114.85M, with a 52-week range of USD 1.6–4.67 (NCM). Source: Nexqual, July 25, 2026 at 10:04 UTC.
Key Statistics (as of July 25, 2026 at 10:04 UTC)
| Price | USD 1.71 |
|---|---|
| Change | ▼ 2.84% (down) |
| Previous Close | USD 1.76 |
| Open | USD 1.76 |
| Day Range | USD 1.7 – 1.77 |
| 52-Week Range | USD 1.6 – 4.67 |
| Volume | 364,418 shares |
| Market Cap | $114.85M |
| Exchange | NCM |
Technical Analysis (MBOT)
Nexqual's technical model rates MBOT "SELL" based on 1 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 10:04 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.05 (neutral) |
| vs SMA50 | Below (USD 1.85) |
| MACD | -0.04 (negative) |
Analyst Ratings (MBOT)
Wall Street analysts rate MBOT "Strong Buy" based on 3 analysts, with a mean price target of USD 7 (range USD 4–12), per Nexqual as of July 25, 2026 at 10:04 UTC.
| Consensus Rating | Strong Buy |
|---|---|
| Analyst Count | 3 |
| Mean Target | USD 7 |
| High Target | USD 12 |
| Low Target | USD 4 |
| Buy / Hold / Sell | 3 / 0 / 0 |
Earnings (MBOT)
| EPS Estimate | USD -0.08 |
|---|---|
| Revenue Estimate | $400,000 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.05 vs est -0.07 ▲ beat |
| 2025-12-31 | USD -0.04 vs est -0.06 ▲ beat |
| 2025-09-30 | USD -0.07 vs est -0.06 ▼ miss |
| 2025-06-30 | USD -0.1 vs est -0.08 ▼ miss |
Source: Nexqual, July 25, 2026 at 10:04 UTC.
Financials & Fundamentals (MBOT)
| Total Revenue | $105,000 |
|---|---|
| Gross Margin | +1.91% |
| Operating Margin | -4114.29% |
| Profit Margin | +0.00% |
| ROE | -27.58% |
| Debt / Equity | 1.21 |
| Current Ratio | 22.6 |
| Total Cash | $72.50M |
| Total Debt | $898,000 |
| Free Cash Flow | $-11.62M |
Source: Nexqual, July 25, 2026 at 10:04 UTC.
Financial Health Score (MBOT)
Nexqual rates Microbot Medical Inc.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 10:04 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $73M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$15M |
| Efficiency | Critical — ROE -28%, ROA -18.4% |
Ownership (MBOT)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +21.85% |
| Shares Outstanding | 67.16M |
| Float | 67.16M |
| Short % of Float | +11.18% |
Source: Nexqual, July 25, 2026 at 10:04 UTC.
Leadership (MBOT)
Microbot Medical Inc. is led by Harel Gadot (age 52), Co-Founder, President, CEO & Chairman, per Nexqual as of July 25, 2026 at 10:04 UTC.
| Co-Founder, President, CEO & Chairman | Harel Gadot (age 52) |
|---|---|
| Chief Financial Officer | Rachel Vaknin (age 46) |
| CTO & GM of Microbot Israel | Simon Sharon MBA, MSc (age 65) |
| Vice President of Sales | Christina Bailey |
| Vice President of Marketing | Allison Rosefort |
Major Backers & Investors (MBOT)
Notable institutional backers of Microbot Medical Inc. include CIBC Bancorp USA Inc., Susquehanna International Group, LLP, UBS Group AG, according to Nexqual as of July 25, 2026 at 10:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| CIBC Bancorp USA Inc. | 2.78% |
| Susquehanna International Group, LLP | 1.38% |
| UBS Group AG | 1.22% |
| DnB Asset Management AS | 1.01% |
| Stifel Financial Corporation | 0.85% |
| Fidelity | 0.85% |
| Marshall Wace LLP | 0.72% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 8.58% |
| BlackRock | 1.53% |
| Geode Capital | 1.13% |
Source: Nexqual, July 25, 2026 at 10:04 UTC.
From Microbot Medical Inc.'s Latest SEC 10-K Filing (filed 2026-03-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Microbot Medical Inc. is a medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space.
- The company offers LIBERTY, an endovascular robotic surgical system designed to maneuver guidewires and over-the-wire devices such as microcatheters within the body's vasculature for use in cardiovascular, peripheral, endovascular, and neurovascular operations.
- It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter.
- The company has a collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system; and Emory University, in connection with autonomous robotics in endovascular procedures.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BPTH | Bio-Path Holdings, Inc. | USD 0.04 | ▲ 0% |
| SNOA | Sonoma Pharmaceuticals, Inc. | USD 1.14 | ▼ 1.72% |
| MBRX | Moleculin Biotech, Inc. | USD 2.12 | ▲ 0.95% |
| APVO | Aptevo Therapeutics Inc. | USD 4.39 | ▼ 1.35% |
| CAPR | Capricor Therapeutics, Inc. | USD 19.7 | ▲ 4.18% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 10:04 UTC. This page is informational and not investment advice.